Relutrigine treatment for people with Developmental and Epileptic Encephalopathy (DEE)
Official title: A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants With DEE Followed by an Open-Label Extension
Run by Praxis Precision Medicines · NCT07010471 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This Phase 3 study will test whether two doses of relutrigine reduce seizures and are safe and tolerable for people with Developmental and Epileptic Encephalopathy.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 2 Years to 65 Years |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | Praxis Precision Medicines Industry-sponsored |
| Locations | 11 sites (La Jolla, California and 10 other locations) |
| Trial ID | NCT07010471 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people with a documented developmental and epileptic encephalopathy with seizure onset before age 12 who meet ECG and safety criteria and weigh more than 7 kg.
✕Probably not a fit
People with certain cardiac rhythm disorders, a recent history of severe convulsive status epilepticus, unstable nerve stimulation devices, or recent participation in other investigational drug studies may not be eligible or derive benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, multi-center, double-blind, placebo-controlled Phase 3 trial comparing two weight-based doses of relutrigine (1.0 mg/kg/day and 1.5 mg/kg/day) against placebo, followed by an open-label extension where participants can receive active drug. Participants must have a documented DEE diagnosis with seizure onset before age 12 and meet basic safety criteria including weight >7 kg and acceptable ECG results. The trial includes safety monitoring, tolerability assessments, and pharmacokinetic sampling to characterize drug levels, along with efficacy endpoints related to seizure frequency and severity. Sites are run by Praxis Precision Medicines at three U.S. locations.
Why it matters
Potential benefit: If successful, relutrigine could reduce seizure frequency and improve clinical outcomes for people with DEE.
How similar studies have gone: Early-phase studies of PRAX-562 (relutrigine) have shown promising safety and seizure-reduction signals in smaller or earlier cohorts, but large randomized Phase 3 evidence in DEE is still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Has a documented diagnosis of a developmental and epileptic encephalopathy. * Onset of seizures \<12 years old. * Has a weight \>7 kg at the time of signing consent/assent. Exclusion Criteria: * Has a history of left bundle branch block, arrhythmias, Brugada syndrome, congenital heart disease, familial short QT syndrome, or family history of sudden death or ventricular arrhythmias, including idiopathic ventricular fibrillation. * Had 2 or more episodes of convulsive status epilepticus requiring hospitalization and intubation in the 6 months prior to Screening. * Has an abnormal ECG reading, including a QT interval corrected for heart rate using Bazett's method (QTcB) \<350 and \>450 ms (males), or \<360 and \>460 ms (females) at Screening and/or on Day 1. * Any nerve stimulation must have been placed at least 3 months prior to Screening with at least 1 month of stable settings prior to Screening. * Has received any other experimental or investigational drug, device, or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, including any prior use of gene therapy. * Is currently pregnant or breastfeeding or is planning to become pregnant during the clinical trial or within 5 half-lives of the last study drug dose.
Where it's running
-
Praxis Research Site
La Jolla, California, United States Recruiting -
Praxis Research Site
Gulf Breeze, Florida, United States Recruiting -
Praxis Research Site
Chevy Chase, Maryland, United States Recruiting -
Praxis Research Site
Roseville, Minnesota, United States Recruiting -
Praxis Research Site
Hackensack, New Jersey, United States Recruiting -
Praxis Research Site
Philadelphia, Pennsylvania, United States Recruiting
Show 5 more locations
-
Praxis Research Site
Heidelberg, Victoria, Australia Recruiting -
Praxis Research Site
Rio Grande, Do Sul, Brazil Recruiting -
Praxis Research Site
Paraná, Brazil Recruiting -
Praxis Research Site
Rio de Janeiro, Brazil Recruiting -
Praxis Research Site
São Paulo, Brazil Recruiting
Study contacts
- Study coordinator: Head of Pharmacovigilance
- Email: clinicaltrials@praxismedicines.com
- Phone: 617-300-8460
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding Pyrimidine and Purine Metabolism Disorders
This study is trying to learn more about pyrimidine and purine metabolism disorders by comparing affected people with their healthy family members to see what factors might influence their condition.
-
Understanding Developmental and Epileptic Encephalopathy through Clinical Data
This study is trying to gather and analyze health information from patients with Developmental and Epileptic Encephalopathy to better understand the condition and improve treatment options.
-
Multi-biomarkers in DEE: a big look at genetic epilepsies
This study tests a panel of multi-omic biomarkers in people with genetically confirmed Developmental and Epileptic Encephalopathy to help understand prognosis and potential biomarkers for future therapies.
-
SLC6A1-NDD: A Longitudinal Look at How the Disorder Progresses
This study follows children and young people with SLC6A1-NDD over two years to see how the condition changes over time and to test which assessments work for future research.
-
S230815 for children with KCNT1-related developmental and epileptic encephalopathy
This study will test whether the investigational medicine S230815 is safe, well tolerated, and affects seizures and related symptoms in children aged 2–12 who have KCNT1-related developmental and epileptic encephalopathy.
-
Elsunersen treatment for infants with early-onset SCN2A-related epileptic encephalopathy
This trial tests whether elsunersen can reduce seizures and is safe in infants and young children with early-onset SCN2A-related developmental and epileptic encephalopathy who have gain-of-function variants.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.